StreetInsider.com News Articles

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025

Sveinn Sölvason, President and CEO, comments:

"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.

Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q3 2025

Tue, 21 Oct 2025 01:31:00 -0400

COPENHAGEN, Denmark, Oct. 21, 2025 /PRNewswire/ --

Announcement no. 49/2025

Embla Medical hf: Interim Report Q3 2025

Tue, 21 Oct 2025 01:31:00 -0400

COPENHAGEN, Denmark, Oct. 21, 2025 /PRNewswire/ --

Announcement no. 49/2025

Embla Medical hf: Interim Report Q3 2025

Tue, 21 Oct 2025 01:31:00 -0400

COPENHAGEN, Denmark, Oct. 21, 2025 /PRNewswire/ --

Announcement no. 49/2025

Embla Medical hf: Interim Report Q3 2025

Tue, 21 Oct 2025 01:31:00 -0400

COPENHAGEN, Denmark, Oct. 21, 2025 /PRNewswire/ --

Announcement no. 49/2025

Embla Medical hf: Interim Report Q3 2025

Tue, 21 Oct 2025 01:31:00 -0400

COPENHAGEN, Denmark, Oct. 21, 2025 /PRNewswire/ --

Announcement no. 49/2025